Biotechnology - Licensing, USA

Filter

Current filters:

LicensingUSA

Popular Filters

1 to 25 of 35 results

Voyager inks up to $845 million deal with Genzyme on novel CNS products

Voyager inks up to $845 million deal with Genzyme on novel CNS products

12-02-2015

US gene therapy start-up company Voyager Therapeutics has entered into a major strategic collaboration…

BiotechnologyGenzymeLicensingNeurologicalResearchSanofiUSAVoyager Therapeutics

RegeneRx links with G-treeBNT to develop RGN-259 in the USA

RegeneRx links with G-treeBNT to develop RGN-259 in the USA

29-01-2015

US biotech firm RegeneRx Biopharmaceuticals has entered into agreements with South Korea-based G-treeBNT…

BiotechnologyG-treeBNTLicensingMergers & AcquisitionsOphthalmicsRegeneRxRGN-259USA

Gilead expands hepatitis C agreements to include sofosbuvir/GS-5816 single tablet regimen

Gilead expands hepatitis C agreements to include sofosbuvir/GS-5816 single tablet regimen

26-01-2015

US biotech major Gilead Sciences has expanded its hepatitis C generic licensing agreements to include…

Anti-viralsBiotechnologyGenericsGilead SciencesIndiaLicensingSovaldiUSA

Celgene exercises option on Agios Pharma’ AG-120

Celgene exercises option on Agios Pharma’ AG-120

14-01-2015

US cancer metabolism specialist Agios Pharmaceuticals says that biotech major Celgene will exercise its…

AG-120Agios PharmaceuticalsBiotechnologyCelgene CorpLicensingOncologyUSA

Emergent BioSolutions acquires EV-035 series of molecules from Evolva Holding

Emergent BioSolutions acquires EV-035 series of molecules from Evolva Holding

17-12-2014

Biopharma company Emergent BioSolutions has acquired the EV-035 series of molecules from Evolva Holding.

Antibiotics and Infectious diseasesBiotechnologyEmergent BioSolutionsEvolvaLicensingResearchUSA

Sorrento to partner with Nantworks founder Patrick Soon-Shiong on immunomodulatory antibodies

Sorrento to partner with Nantworks founder Patrick Soon-Shiong on immunomodulatory antibodies

15-12-2014

Oncology specialist Sorrento Therapeutics has entered into a binding agreement with medical technology…

BiotechnologyLicensingOncologyResearchSorrento TherapeuticsUSA

Spark Thera in potential $280 million hemophilia B deal with Pfizer

Spark Thera in potential $280 million hemophilia B deal with Pfizer

10-12-2014

US gene therapy start up Spark Therapeutics has entered into a global collaboration with pharma giant…

BiotechnologyHematologyLicensingPfizerSpark TherapeuticsSPK-RPE65USA

Dicerna licenses rights to Tekmira technology

Dicerna licenses rights to Tekmira technology

18-11-2014

US RNAi therapeutics specialist Dicerna Pharmaceuticals has entered a licensing agreement for to use…

BiotechnologyDCR-PH1Dicerna PharmaceuticalsLicensingRare diseasesTekmira PharmaceuticalsUSA

Merck enters lucrative cancer alliance with Pfizer

Merck enters lucrative cancer alliance with Pfizer

17-11-2014

Germany’s Merck KGaA said today that it has entered into a global agreement with US pharma giant Pfizer…

BiotechnologyGermanyLicensingMarkets & MarketingMerck KGaAMerck SeronoMSB0010718COncologyPfizerUSAXalkori

Onxeo receives $25M milestone payment from Spectrum on Beleodaq

14-11-2014

Onxeo, created by a merger between French company BioAlliance Pharma, and Danish biopharmaceutical company…

BeleodaqBiotechnologyFinancialHematologyLicensingOncologyOnxeoSpectrum PharmaceuticalsUSA

AVEO inks deal with Ophthotech for tivozanib in ocular diseases

AVEO inks deal with Ophthotech for tivozanib in ocular diseases

11-11-2014

US biotech firm AVEO Oncology has entered into a research and exclusive option agreement with Ophthotech…

AVEO OncologyBiotechnologyLicensingOphthalmicsOphthotechtivozanibUSA

Ferrer buys $8 million of Alexza shares, to eliminate certain Adasuve milestone payments

Ferrer buys $8 million of Alexza shares, to eliminate certain Adasuve milestone payments

28-10-2014

US drugmaker Alexza Pharmaceuticals and privately-held Spanish firm Grupo Ferrer Internacional have amended…

AdasuveAlexza PharmaceuticalBiotechnologyFerrer InternacionalFinancialLicensingNeurologicalUSA

CTI acquires tosedostat rights from Vernalis and Chroma

CTI acquires tosedostat rights from Vernalis and Chroma

27-10-2014

Blood-related cancer specialist CTI BioPharma has acquired the worldwide rights to tosedostat through…

BiotechnologyChroma TherapeuticsCTI BioPharmaLicensingOncologytosedostatUSAVernalis

PhosImmune and PureMHC to collaborate on antibody-based immunotherapies for cancer

PhosImmune and PureMHC to collaborate on antibody-based immunotherapies for cancer

22-10-2014

Clinical-stage oncology biotech company PhosImmune has entered into a license and collaboration agreement…

BiotechnologyLicensingOncologyPhosImmunePureMHCUSA

New Coronado Biosciences unit to acquire and license dermatology products for commercialization

New Coronado Biosciences unit to acquire and license dermatology products for commercialization

08-10-2014

US biopharma company Coronado Biosciences has formed a wholly-owned subsidiary, Journey Medical Corporation…

BiotechnologyCoronado BiosciencesDermatologicalsJourney Medical CorpLicensingManagementUSA

Baxter and Merrimack enter exclusive licensing agreement for MM-398 compound outside the USA

Baxter and Merrimack enter exclusive licensing agreement for MM-398 compound outside the USA

24-09-2014

Baxter International and oncology specialist Merrimack have launched a collaboration to develop and commercialize…

Baxter InternationalBiotechnologyLicensingMerrimackMM-398OncologyUSA

Merck unit inks antibody drug conjugates deal with Sutro Biopharma

Merck unit inks antibody drug conjugates deal with Sutro Biopharma

18-09-2014

EMD Serono, a US subsidiary of Germany’s Merck KGaA has entered into a collaboration and license agreement…

BiotechnologyEMD SeronoLicensingMerck KGaAOncologyResearchUSA

ViaCyte gets $20 million in deal with Janssen

ViaCyte gets $20 million in deal with Janssen

22-08-2014

Privately held US regenerative medicine company ViaCyte has entered into a rights agreement with Janssen…

BiotechnologyDiabetesEndocrine systemFinancialJanssenJohnson & JohnsonLicensingUSAVC-01ViaCyte

Emergent BioSolutions and MorphoSys to co-develop prostate cancer drug candidate ES414

Emergent BioSolutions and MorphoSys to co-develop prostate cancer drug candidate ES414

20-08-2014

US biopharmaceutical firm Emergent BioSolutions and Germany’s MorphoSys have entered into an agreement…

BiotechnologyEmergent BioSolutionsES414GermanyLicensingMOR209/ES414MorphoSysOncologyProstate cancerUSA

Ligand signs Captisol license deal with Avion Pharmaceuticals

Ligand signs Captisol license deal with Avion Pharmaceuticals

15-08-2014

Ligand Pharmaceuticals has signed a commercial license agreement with fellow USA-based Avion Pharmaceuticals,…

Avion PharmaceuticalsBiotechnologyBusiness FinanceCaptisolLicensingLigand PharmaceuticalsUSA

TNI BioTech and Hubei Qianjiang link up on cancer drug development

TNI BioTech and Hubei Qianjiang link up on cancer drug development

13-08-2014

US biotech firm TNI BioTech has signed a supplemental agreement with China’s Hubei Qianjiang Pharmaceutical…

BiotechnologyBusiness FinanceChinaHubeiLicensingOncologyQianjiang PharmaceuticalResearchTNI BioTechUSA

Theraclone out-licenses HIV bNAbs to Gilead

Theraclone out-licenses HIV bNAbs to Gilead

01-08-2014

US privately-held drug developer Theraclone Sciences has entered into an agreement with biotech major…

Anti-viralsBiotechnologyBusiness FinanceGilead SciencesHIV/AIDSLicensingTheraclone SciencesUSA

Shire in strategic collaboration with ArmaGen for Hunter syndrome

Shire in strategic collaboration with ArmaGen for Hunter syndrome

23-07-2014

Ireland-headquartered drugmaker Shire has entered into an agreement with US privately held biotech company…

AGT-182ArmagenBiotechnologyCNS DiseasesHunter syndromeIrelandLicensingShireUSA

Puma Biotech rockets on new neratinib data; amends deal with Pfizer

Puma Biotech rockets on new neratinib data; amends deal with Pfizer

23-07-2014

US development-stage company Puma Biotechnology saw its share more than triple to $190 in after-hours…

BiotechnologyLicensingneratinibOncologyPB272PfizerPuma BiotechResearchTrastuzumabUSA

1 to 25 of 35 results

COMPANY SPOTLIGHT

Menarini

Back to top